Alamar Biosciences
38.13USD+10.97%Share
Alamar Biosciences, Inc., a proteomics company, develops a proteomic liquid biopsy platform and sells instruments, consumables, and services to early detection of diseases.
What's happening?
ALMR is outpacing Healthcare this month: +23.8% against +3.8% for the average Healthcare stock.
Listed 17 April 2026: no trend reading until about 28 January 2027 · 24 of 34 Healthcare stocks are trending up.
- 1D
- +10.97%
- 7D
- +16.93%
- 1M
- +23.80%
- 3M
- +48.60%
- 6M
- —
- YTD
- —
What is the market expecting?
No forward P/E, as a loss is expected; analysts' mean target sits 7.2% below the price.
Not ranked on value yet: the ranking reads the stocks on the board, which this one joins with its first trend reading.
Is the business delivering?
Revenue +82.1% on a year ago; met or beat the estimate last quarter.
Earnings by quarter
Latest quarter -13.2M
- -13.2MAug26—
Net income from the income statement, in USD, by the month it was reported.
How does it compare?
Value rankingALMR is not ranked on value, so there are no nearest stocks to set it against.
What happens next?
Reports next on 5 Nov, in 31 days.
Fundamentals
In the briefing
Briefing for 5 OctThe briefing has not named ALMR.
Keep researching
Where next from ALMR
Daily market updates
Get the daily brief
Get an interesting stock pick, updates on the AI sector, information on the biggest movers of the day, and more, in the Monday to Saturday email.